1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Respiratory Tract Infections - Pipeline Review, H2 2013

Respiratory Tract Infections - Pipeline Review, H2 2013

  • November 2013
  • -
  • Global Markets Direct
  • -
  • 63 pages

Respiratory Tract Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Respiratory Tract Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Infections. Respiratory Tract Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Respiratory Tract Infections.
- A review of the Respiratory Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Respiratory Tract Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Respiratory Tract Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Respiratory Tract Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Respiratory Tract Infections - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Respiratory Tract Infections Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Respiratory Tract Infections 8
Respiratory Tract Infections Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Respiratory Tract Infections Therapeutics - Products under Development by Companies 16
Companies Involved in Respiratory Tract Infections Therapeutics Development 17
Johnson and Johnson 17
Shionogi and Co., Ltd. 18
GlaxoSmithKline plc 19
Daiichi Sankyo Company, Ltd 20
Taisho Pharmaceutical Co., Ltd. 21
Nanotherapeutics, Inc. 22
Cubist Pharmaceuticals, Inc. 23
Nippon Shinyaku Co., Ltd. 24
Dongwha Pharm Co., Ltd. 25
Novabiotics Ltd 26
iBio, Inc. 27
Afexa Life Sciences Inc. 28
Respiratory Tract Infections - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
gentamicin sulfate - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
cidofovir - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
CVT-E002 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
prulifloxacin - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
zabofloxacin - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Anthrax Monoclonal Antibody - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
GSK-2140944 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
S-649266 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Novarifyn - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
PL-401 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
PL-402 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Antibacterial Drug - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Compound-G1 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Compound-2a - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Pam2Cys - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Drug For Respiratory Tract Infections - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Respiratory Tract Infections Therapeutics - Drug Profile Updates 53
Respiratory Tract Infections Therapeutics - Discontinued Products 55
Respiratory Tract Infections Therapeutics - Dormant Products 56
Respiratory Tract Infections - Product Development Milestones 57
Featured News and Press Releases 57
Apr 11, 2011: Arbor Pharmaceuticals Acquires Erythromycin Products From Abbott Laboratories 57
Jan 10, 2011: Mpex Initiates Aeroquin Phase III Trial For Treatment Of Chronic Bacterial Infections In Cystic Fibrosis Patients 57
Oct 21, 2010: Transave Announces 's Arikace Demonstrates Sustained Benefit In Multiple Studies Of Pseudomonas Lung Infections In Cystic Fibrosis Patients 58
Oct 04, 2010: The conclusion of a license agreement for an antibacterial agent ‘Prulifloxacin' 59
Aug 24, 2009: Nanotherapeutics Awarded $30.9 Million NIAID Contract To Develop Inhaled Antiviral For Prophylaxis And Treatment Of Smallpox 59
Mar 03, 2009: The conclusion of a license agreement for an antibacterial agent ‘Prulifloxacin' in China 60
Oct 27, 2004: Launch of Nippon Shinyaku's quinolone antibacterial agent in Italy 60
Jun 28, 2004: The conclusion of Licensing Agreement for an antibacterial agent 'Prulifloxacin' in the U.S. 60
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63



List of Tables

Number of Products Under Development for Respiratory Tract Infections, H2 2013 8
Products under Development for Respiratory Tract Infections - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Clinical Stage Development, H2 2013 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Johnson and Johnson, H2 2013 17
Shionogi and Co., Ltd., H2 2013 18
GlaxoSmithKline plc, H2 2013 19
Daiichi Sankyo Company, Ltd, H2 2013 20
Taisho Pharmaceutical Co., Ltd., H2 2013 21
Nanotherapeutics, Inc., H2 2013 22
Cubist Pharmaceuticals, Inc., H2 2013 23
Nippon Shinyaku Co., Ltd., H2 2013 24
Dongwha Pharm Co., Ltd., H2 2013 25
Novabiotics Ltd, H2 2013 26
iBio, Inc., H2 2013 27
Afexa Life Sciences Inc., H2 2013 28
Assessment by Monotherapy Products, H2 2013 29
Assessment by Stage and Route of Administration, H2 2013 31
Assessment by Stage and Molecule Type, H2 2013 33
Respiratory Tract Infections Therapeutics - Drug Profile Updates 53
Respiratory Tract Infections Therapeutics - Discontinued Products 55
Respiratory Tract Infections Therapeutics - Dormant Products 56



List of Figures

Number of Products under Development for Respiratory Tract Infections, H2 2013 8
Products under Development for Respiratory Tract Infections - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Late Stage Products, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Early Clinical Stage Products, H2 2013 14
Discovery and Pre-Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 29
Assessment by Route of Administration, H2 2013 30
Assessment by Stage and Route of Administration, H2 2013 31
Assessment by Molecule Type, H2 2013 32
Assessment by Stage and Molecule Type, H2 2013 33



Companies Mentioned

Johnson and Johnson
Shionogi and Co., Ltd.
GlaxoSmithKline plc
Daiichi Sankyo Company, Ltd
Taisho Pharmaceutical Co., Ltd.
Nanotherapeutics, Inc.
Cubist Pharmaceuticals, Inc.
Nippon Shinyaku Co., Ltd.
Dongwha Pharm Co., Ltd.
Novabiotics Ltd
iBio, Inc.
Afexa Life Sciences Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.